98%
921
2 minutes
20
Objective: The CHADS-VASc score and left atrial epicardial adipose tissue (LA-EAT) volume have been identified as potential risk factors for atrial fibrillation (AF) recurrence after ablation. However, there is currently a lack of research specifically examining the interaction between these two AF risk factors. This study aims to evaluate the predictive potential of combining CHADS-VASc score and LA-EAT volume in predicting recurrence in patients with AF who undergo ablation.
Methods: The study encompassed a cohort of 507 patients who underwent ablation for AF finally. Follow-up assessments were conducted 1, 3, 6, and 12 months after ablation, including clinical evaluation, a 12-lead ECG, and 24-hour Holter monitoring. Recurrence was characterized by symptomatic or asymptomatic AF episodes or atrial tachycardia lasting more than 30 seconds, as evidenced by any ECG following the 3-month BP. Patients were stratified into groups based on the defined cut-off values of CHADS-VASc score and LA-EAT volume. Cox regression analysis was employed to estimate the risk factor of AF recurrence after ablation. The interaction between CHADS-VASc score and LA-EAT volume was assessed using the relative excess risk due to interaction (RERI), attributable proportion (AP), and synergy index (SI).
Results: 140 patients experienced AF recurrence after ablation during the follow-up period. Multivariable Cox regression analysis demonstrated that CHADS-VASc score and LA-EAT volume were independent risk factors for AF recurrence. Patients with higher CHADS-VASc score and LA-EAT volume exhibited a higher risk of recurrence than those with lower score and volume. Furthermore, a significant synergistic interaction existed between CHADS-VASc score and LA-EAT volume. The LA-EAT volume and clinical model combination improved the predictive value reclassification, and discriminant abilities improved significantly.
Conclusion: There is a significant additive interaction between CHADS-VASc score and LA-EAT volume, with the coexistence of both factors significantly increasing the risk of AF recurrence after ablation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913026 | PMC |
http://dx.doi.org/10.2147/TCRM.S504531 | DOI Listing |
CJC Open
April 2025
University of Toronto, Toronto, Ontario, Canada.
Background: Optimal thromboprophylaxis in atrial fibrillation (AF) requires the accurate application of modern clinical guidelines. We evaluated the point prevalence and factors associated with nonguideline-directed anticoagulation and direct oral anticoagulant (DOAC) dosing in Canadian patients with AF.
Methods: TRANSECT-AF is a retrospective registry of consecutive Canadian patients with AF collected between March 2021 and August 2023.
Rev Med Interne
March 2025
Département de cardiologie, CHRU de Nancy, 1, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France; IADI, Inserm U1254, Université de Lorraine, Nancy, 1, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France.
Atrial fibrillation (AF) is the most common arrhythmia. It increases the risk of hospitalization, heart failure, cognitive decline and mortality. It is the first cause of ischemic stroke.
View Article and Find Full Text PDFHosp Pharm
December 2024
Maxor National Pharmacy Services Corp, Amarillo, TX, USA.
This study examines the correlation between time-in-therapeutic range (TTR) and anticoagulation-related adverse events (AEs) in patients with atrial fibrillation (Afib) in a pharmacist-managed ambulatory care clinic. A single-center, retrospective cohort study was conducted at a community hospital-based outpatient anticoagulation clinic to investigate the predictive value of suboptimal TTR percentages for hemorrhagic or thromboembolic events in Afib patients. Eligible participants were aged 18 years or older, diagnosed with Afib, and receiving warfarin therapy as current or past enrollees in the anticoagulation management program.
View Article and Find Full Text PDFJAMA Cardiol
October 2024
Department of Cardiology, Hospital Universitari de la Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain.
J Clin Med
June 2024
Surgical, Medical, Dental and Morphological Sciences Department (CHIMOMO), University of Modena and Reggio Emilia, 41126 Modena, Italy.
: The necessity of using central venous catheters (CVCs) in hemodialysis, coupled with their associated complications, remains a critical concern in nephrology. This study aims to compare the short-term prognosis of tunneled (T-CVC) and non-tunneled (NT-CVC) CVCs in acute hemodialysis patients, specifically focusing on infection rates, malpositioning, and lumen thrombosis within the first three weeks post-insertion. : A retrospective analysis was conducted on 176 CVCs placed between January and December 2023 at the Policlinico di Modena and the Ospedale Civile di Baggiovara.
View Article and Find Full Text PDF